OrthoPediatrics Corp. (KIDS)
| Market Cap | 465.93M -8.3% |
| Revenue (ttm) | 243.30M +14.5% |
| Net Income | -39.68M |
| EPS | -1.68 |
| Shares Out | 25.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,342 |
| Open | 17.73 |
| Previous Close | 17.72 |
| Day's Range | 17.48 - 18.40 |
| 52-Week Range | 14.42 - 23.70 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 24.67 (+36.0%) |
| Earnings Date | Apr 30, 2026 |
About KIDS
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruct... [Read more]
Financial Performance
In 2025, OrthoPediatrics's revenue was $236.35 million, an increase of 15.45% compared to the previous year's $204.73 million. Losses were -$39.65 million, 4.83% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for KIDS stock is "Buy." The 12-month stock price target is $24.67, which is an increase of 36.00% from the latest price.
News
OrthoPediatrics price target lowered to $17 from $20 at Truist
Truist lowered the firm’s price target on OrthoPediatrics (KIDS) to $17 from $20 and keeps a Hold rating on the shares. The firm notes that sales upside relative to consensus…
OrthoPediatrics expands specialty bracing portfolio with Traxio launch
OrthoPediatrics (KIDS) announced the launch of the Traxio Complete Weight System, in collaboration with Synetik Group, Inc. “The introduction of TRAXIO reflects our ongoing commitment to advancing ped...
OrthoPediatrics reports Q1 EPS (42c), consensus (48c)
Reports Q1 revenue $59.36M, consensus $58.32M. David Bailey, President & CEO of OrthoPediatrics (KIDS), commented, “We delivered a strong start to 2026 with 13% first quarter revenue growth and signif...
OrthoPediatrics sees FY26 revenue $263M-$267M, consensus $264.31M
Previous view was $262M-$266M.
OrthoPediatrics Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% revenue growth, strong international and OPSB expansion, and improved profitability. Guidance was raised for 2026, with new product launches and regulatory wins expected to drive further growth and margin expansion.
OrthoPediatrics Earnings release: Q1 2026
OrthoPediatrics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
OrthoPediatrics Quarterly report: Q1 2026
OrthoPediatrics has published its Q1 2026 quarterly earnings report on April 30, 2026.
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System
WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics price target raised to $25 from $24 at Canaccord
Canaccord raised the firm’s price target on OrthoPediatrics (KIDS) to $25 from $24 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results.
OrthoPediatrics Proxy statement: Proxy filing
OrthoPediatrics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
OrthoPediatrics Proxy statement: Proxy filing
OrthoPediatrics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
WARSAW, Ind., April 16, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Transcript: 25th Annual Needham Virtual Healthcare Conference
Clinic expansion is ahead of schedule, with strong revenue and cash flow improvements. New enabling technologies and a robust product pipeline are driving growth, while international and digital initiatives are expanding. Financial outlook remains stable with improved margins and cash flow.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WARSAW, Ind., March 31, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Transcript: The Citizens Life Sciences Conference 2026
A robust new product cycle is underway, with multiple launches in surgical, bracing, and enabling tech segments expected to drive growth through 2028. Financial performance is improving, with positive free cash flow targeted for 2026 and ongoing expansion of the specialty bracing business. Reduced competition due to regulatory changes is creating additional market opportunities.
OrthoPediatrics Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 results included the first quarter of positive free cash flow and robust EBITDA growth. 2026 guidance targets 11%-13% revenue growth, $25M adjusted EBITDA, and break-even cash flow, driven by new product launches, international expansion, and a unique pediatric focus that limits competition.
OrthoPediatrics price target raised to $20 from $19 at Truist
Truist raised the firm’s price target on OrthoPediatrics (KIDS) to $20 from $19 and keeps a Hold rating on the shares. The company’s Q4 EBITDA and free cash flow generation…
OrthoPediatrics price target raised to $22 from $20 at Stifel
Stifel raised the firm’s price target on OrthoPediatrics (KIDS) to $22 from $20 and keeps a Buy rating on the shares.
OrthoPediatrics price target raised to $24 from $23 at BTIG
BTIG analyst Ryan Zimmerman raised the firm’s price target on OrthoPediatrics (KIDS) to $24 from $23 and keeps a Buy rating on the shares. The company is making steady progress…
OrthoPediatrics to Participate in Upcoming Conferences
WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Slides: Investor presentation
OrthoPediatrics has posted slides in relation to its latest quarterly earnings report, which was published on February 27, 2026.
OrthoPediatrics Earnings Call Transcript: Q4 2025
Q4 2025 saw 17% revenue growth, record free cash flow, and strong gross margins, driven by innovation and international expansion. 2026 guidance projects 11%-13% revenue growth, $25M Adjusted EBITDA, and breakeven FCF, with a robust product pipeline and new market entries.
OrthoPediatrics Annual report: Q4 2025
OrthoPediatrics has published its Q4 2025 annual report on February 26, 2026.
OrthoPediatrics Earnings release: Q4 2025
OrthoPediatrics released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.